A Gastrointestinal Quality of Life Study in Lung Transplant Recipients Converted From Mycophenolate Mofetil to Myfortic

Stopped early · Not applicable

Conditions studied: Lung Transplantation

In brief

The primary objective of this study is to evaluate gastrointestinal (GI) symptoms and health related quality of life in lung transplant recipients converted from Mycophenolate Mofetil (MMF) to Myfortic as part of standard immunosuppressive therapy.

Key facts

Study ID

NCT01044667

Run by

Vanderbilt University

People needed

3

Starts

2010-01-01

Expected to finish

2012-12-01

Last updated by the study team

2018-02-20

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ability and willingness to provide written informed consent and adhere to study regimen
• Recipients who are 18-70 years of age
• Patients who have undergone either single or double lung transplant are discharged on the standard MMF (no generic MMF will be used) therapy and complain of GI symptoms, thought to be related to their immunosuppressive regimen

You may not qualify if…

• Patients who have GI complaints thought to be due to factors other than immunosuppressive regimen
• Patients receiving steroid treatment for acute rejection
• Women of childbearing potential who do not agree to use at least two acceptable forms of contraception prior to starting study drug, while taking study drug, and for 6 weeks after stopping study drug
• Women who have a positive serum or urine pregnancy test at visit 1 and/or continuing through the study

Where it is running

• Vanderbilt University Medical Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.